Proton Pump Inhibitor Therapy and Hepatic Encephalopathy Risk in Cirrhotic Patients: A Systematic Review with Meta-analysis
- 173 Downloads
Background and Objectives
Use of proton pump inhibitor (PPI) in patients with cirrhosis has been linked to the development of hepatic encephalopathy (HE). Little is known about the incidence rate of HE due to PPI therapy. We conducted a meta-analysis to explore the association between PPI use and the incidence of HE.
We searched PubMed, EMBASE databases and The Cochrane Library from inception to March 2019 for studies describing the association between PPI exposure and incidence of HE; we identified studies that provided the adjusted estimates of odds ratio (OR)/relative ratio (RR)/hazard ratio (HR), and the pooled RRs on the incidence of HE were calculated. Summary estimates were calculated using random effects models.
We analyzed data from 10 eligible studies; PPI users had an increased risk of HE compared with non-PPI user, with a pooled RR of 1.81 (95% CI 1.58–2.06), with notable heterogeneity (I2 = 85.2%, p <0.0001). In subgroup of considering the incidence of HE after yrans-jugular intrahepatic portosystemic shunt (TIPS), the pooled RR was 3.09 (95% CI 2.23–4.27), with no statistical heterogeneity (I2 = 0.0%, p = 0.484); another subgroup analysis was conducted for the complication of the enrolled patients with the status of ascites, the pooled RR was 1.39 (95% CI 1.10–1.77). The result of statistical heterogeneity was low (I2 = 46.2%, p = 0.156).
We found PPI therapy increased the risk of HE in cirrhotic patients, and higher risk was found in post-operative TIPS. Additional studies are warranted to inform clinical decision making.
The authors are very grateful to all staffs of the Department of Pharmacy at First Affiliated Hospital of Wenzhou Medical University and Department of Anesthesiology at Second Affiliated Hospital of Wenzhou Medical University.
Compliance with Ethical Standards
No sources of funding were received for the preparation of this study.
Conflict of interest
Dawei Shi, Ziye Zhou, Ying Dai, Xiaofeng Pan, Qinqin Cao have no conflicts of interest that are directly relevant to the content of this systematic review and meta-analysis.
Guarantor of the article: Dawei Shi.
DS and ZZ designed the study, then screened titles and abstracts resulting from the search. YD and QC involved in the data extraction. DS performed the statistical analysis, interpreted the results and wrote the draft. XP helped with language editing and critically revised the manuscript.
- 3.Zhu J, Qi X, Yu H, et al. Acid suppression in patients treated with endoscopic therapy for the management of gastroesophageal varices: a systematic review and meta-analysis. Expert Rev Gastroenterol Hepatol. 2018;2018(17474124):1456918.Google Scholar
- 12.O’Leary JG, Reddy KR, Wong F, et al. Long-term use of antibiotics and proton pump inhibitors predict development of infections in patients with cirrhosis. Clin Gastroenterol Hepatol. 2015;13(753–9):e2.Google Scholar
- 16.Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions (version 5.0.1). London: The Cochrane Collaboration; 2011.Google Scholar
- 18.Wells GA, Shea B, O’Connell D, et al. The Newcastle–Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses [EB/OL]. http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm. Accessed 30 Mar 2019.
- 19.Rostom A, Dube C, Cranney A, et al. Celiac disease. Rockville (MD): agency for healthcare research and quality (US); 2004 Sep. (Evidence Reports/Technology Assessments, No. 104.) Appendix D. Quality assessment forms. http://www.ncbi.nlm.nih.gov/books/NBK35156. Accessed 30 Mar 2019.
- 30.Shanab AA, Smith A, Abbas M, et al. Proton pump inhibitors-a risk factor for hepatic encephalopathy in patients listed for liver transplantation? Hepatology. 2018;68:1176A.Google Scholar